CN109890398B - 可用于治疗心脏疾病并含有成纤维细胞的注射用组合物以及用于生产用于治疗用途的成纤维细胞的方法 - Google Patents

可用于治疗心脏疾病并含有成纤维细胞的注射用组合物以及用于生产用于治疗用途的成纤维细胞的方法 Download PDF

Info

Publication number
CN109890398B
CN109890398B CN201880003050.1A CN201880003050A CN109890398B CN 109890398 B CN109890398 B CN 109890398B CN 201880003050 A CN201880003050 A CN 201880003050A CN 109890398 B CN109890398 B CN 109890398B
Authority
CN
China
Prior art keywords
fibroblasts
cells
positive
less
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880003050.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN109890398A (zh
Inventor
岩宫贵纮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lymphatic Orgnex Co ltd
Original Assignee
Metcela Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metcela Inc filed Critical Metcela Inc
Publication of CN109890398A publication Critical patent/CN109890398A/zh
Application granted granted Critical
Publication of CN109890398B publication Critical patent/CN109890398B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880003050.1A 2017-02-24 2018-02-23 可用于治疗心脏疾病并含有成纤维细胞的注射用组合物以及用于生产用于治疗用途的成纤维细胞的方法 Active CN109890398B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017033624 2017-02-24
JP2017-033624 2017-02-24
PCT/JP2018/006795 WO2018155651A1 (ja) 2017-02-24 2018-02-23 線維芽細胞を含む心臓疾患を治療するための注射用組成物、及び治療用線維芽細胞の製造方法

Publications (2)

Publication Number Publication Date
CN109890398A CN109890398A (zh) 2019-06-14
CN109890398B true CN109890398B (zh) 2024-01-16

Family

ID=63253929

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880003050.1A Active CN109890398B (zh) 2017-02-24 2018-02-23 可用于治疗心脏疾病并含有成纤维细胞的注射用组合物以及用于生产用于治疗用途的成纤维细胞的方法

Country Status (12)

Country Link
US (2) US11096969B2 (enExample)
EP (1) EP3476395B1 (enExample)
JP (2) JP6618066B2 (enExample)
KR (1) KR102407387B1 (enExample)
CN (1) CN109890398B (enExample)
AU (1) AU2018223739B2 (enExample)
CA (1) CA3032654A1 (enExample)
DK (1) DK3476395T3 (enExample)
ES (1) ES2885080T3 (enExample)
IL (1) IL267958B2 (enExample)
SG (1) SG11201900810WA (enExample)
WO (1) WO2018155651A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3110831A1 (en) 2018-08-29 2020-03-05 Metcela Inc. Method for producing fibroblast, and g-csf-positive fibroblast mass
CN109589337B (zh) 2018-12-29 2022-04-26 南京艾尔普再生医学科技有限公司 心肌细胞制剂及其制备方法和应用
IL296125A (en) 2020-03-04 2022-11-01 Metcela Inc Fibroblasts have an increased ability to produce erythropoietin
AU2022231584A1 (en) * 2021-03-04 2023-09-07 Lymphogenix Limited Lymphangiogenesis promoting factor-expressing fibroblast, and pharmaceutical composition containing same
US20240316113A1 (en) * 2021-09-08 2024-09-26 Metcela Inc. Fibroblast-containing pharmaceutical composition for treating kidney disease
EP4249585A1 (en) * 2022-03-25 2023-09-27 Technische Universität München - TUM Heart tissue models, method of producing heart tissue models and uses of heart tissue models

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101820890A (zh) * 2007-08-03 2010-09-01 崔克斯基因有限公司 心脏脂肪组织来源的成体干细胞群及其在心脏再生中的用途
CN103202857A (zh) * 2003-03-28 2013-07-17 中胚有限公司 血管周围间充质前体细胞诱导的血管形成
WO2016006262A1 (ja) * 2014-07-11 2016-01-14 貴紘 岩宮 心臓細胞培養材料

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2487254A1 (en) * 2002-05-08 2003-11-20 The Regents Of The University Of California System and method for treating cardiac arrhythmias with fibroblast cells
AU2003239418B2 (en) * 2002-05-08 2008-01-31 The Regents Of The University Of California System and method for forming a non-ablative cardiac conduction block
US20040161412A1 (en) * 2002-08-22 2004-08-19 The Cleveland Clinic Foundation Cell-based VEGF delivery
US7470538B2 (en) * 2002-12-05 2008-12-30 Case Western Reserve University Cell-based therapies for ischemia
CN101415458A (zh) * 2003-11-10 2009-04-22 辛弗尼医药有限公司 控制心房纤维性颤动患者心室律的方法
US8513011B2 (en) * 2004-08-26 2013-08-20 Biotech Research Ventures Pte Limited Methods and compositions for culturing cardiomyocyte-like cells
JP5378743B2 (ja) 2008-09-30 2013-12-25 テルモ株式会社 医療用細胞シートの製造方法
WO2013028968A1 (en) * 2011-08-25 2013-02-28 Wisconsin Alumni Research Foundation 3-dimensional cardiac fibroblast derived extracellular matrix
EP2826855B1 (en) 2012-03-15 2018-08-29 iHeart Japan Corporation Myocardial sheet
US20140072611A1 (en) * 2012-09-07 2014-03-13 Fibrocell Technologies, Inc. Methods and Compositions for Treating Post-Cardial Infarction Damage
GB201309057D0 (en) * 2013-05-20 2013-07-03 Cell Therapy Ltd Method
KR20150009655A (ko) * 2013-07-16 2015-01-27 학교법인 동아학숙 Gcp-2 유전자를 과발현하는 지방 간엽줄기세포를 포함하는 허혈성 질환 치료용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103202857A (zh) * 2003-03-28 2013-07-17 中胚有限公司 血管周围间充质前体细胞诱导的血管形成
CN101820890A (zh) * 2007-08-03 2010-09-01 崔克斯基因有限公司 心脏脂肪组织来源的成体干细胞群及其在心脏再生中的用途
WO2016006262A1 (ja) * 2014-07-11 2016-01-14 貴紘 岩宮 心臓細胞培養材料

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Cardiac fibrobialst-derived VCAM-1 enhances cardiomyocyte proliferation for fabrication of bioengineered cardiac tissue;TAKAHIRO IWAMIYA等;《REGENERATIVE THERAPY》;20160601;全文 *
Discovery of a specific type of cardiac fibroblasts ameliorating chronic heart failure;TAKAHIRO IWAMIYA等;《BAIOSAIENSU TO INDASUTORI-BIOSCIENCE TO INDUSTRY》;20180101;全文 *
Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice;KATSUHISA MATSUURA等;《JOURNAL OF CLINICAL INVESTIGATION》;20090713;全文 *

Also Published As

Publication number Publication date
EP3476395A4 (en) 2020-02-26
SG11201900810WA (en) 2019-02-27
CN109890398A (zh) 2019-06-14
IL267958A (en) 2019-09-26
AU2018223739A1 (en) 2019-02-14
US20210346436A1 (en) 2021-11-11
EP3476395A1 (en) 2019-05-01
CA3032654A1 (en) 2018-08-30
IL267958B2 (en) 2023-08-01
JP7072135B2 (ja) 2022-05-20
IL267958B1 (en) 2023-04-01
EP3476395B1 (en) 2021-07-21
WO2018155651A1 (ja) 2018-08-30
DK3476395T3 (da) 2021-08-16
JP2019218408A (ja) 2019-12-26
JP6618066B2 (ja) 2019-12-11
US20190224250A1 (en) 2019-07-25
KR20190117468A (ko) 2019-10-16
US11096969B2 (en) 2021-08-24
AU2018223739B2 (en) 2023-06-22
KR102407387B1 (ko) 2022-06-10
JPWO2018155651A1 (ja) 2019-11-07
ES2885080T3 (es) 2021-12-13

Similar Documents

Publication Publication Date Title
CN109890398B (zh) 可用于治疗心脏疾病并含有成纤维细胞的注射用组合物以及用于生产用于治疗用途的成纤维细胞的方法
Bao et al. C-Kit Positive cardiac stem cells and bone marrow–derived mesenchymal stem cells synergistically enhance angiogenesis and improve cardiac function after myocardial infarction in a paracrine manner
JP7528149B2 (ja) 心不全の治療方法
CN114164174A (zh) 含有适合用于缺血性疾病治疗的细胞的细胞群体的体外增殖方法
CN108472319A (zh) 用于治疗心脏病的移植材料
JP2024515690A (ja) 疾患の治療のための間葉系間質細胞からの細胞外小胞
EP3845635A1 (en) Method for producing fibroblast, and g-csf-positive fibroblast mass
CN106701668B (zh) 间质干细胞、其纯株化扩张的方法及其应用
JP5894071B2 (ja) 心臓組織由来細胞
JP2018530992A6 (ja) 間葉系幹細胞、そのクローン原性増殖方法、分離方法及び用途
CN108486046B (zh) 一种抗缺氧损伤的干细胞制剂及其制备方法与在制备治疗急性心梗药物中的应用
EP2068897A1 (en) Endothelial progenitor cell compositions and neovascularization
JP2021066732A (ja) 脂肪由来血管内皮（前駆）細胞を含む細胞集団を含む医薬組成物
CN117120063A (zh) 淋巴管新生促进因子表达成纤维细胞以及含有该细胞的医药组合物
Seung Mesenchymal stem cells promote infiltration of myeloid-derived suppressor cells after acute myocardial infarction via up-regulation of multiple cytokines
Kinugawa et al. Safety and Efficacy of Autologous Skeletal Myoblast Sheets (TCD-5 1073) for the Treatment of Severe Chronic Heart

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20241112

Address after: London

Patentee after: Lymphatic Orgnex Co.,Ltd.

Country or region after: Britain

Address before: Yamagata Prefecture, Japan

Patentee before: METCELA Inc.

Country or region before: Japan